Exploring the effects and mechanism of peony pollen in treating benign prostatic hyperplasia

被引:0
|
作者
Mu, Jun [1 ]
Wu, Junsheng [1 ]
Duan, Linrui [1 ]
Yang, Qian [2 ]
Liu, Xiaoting [1 ]
Bai, Huixin [1 ]
Xie, Yanhua [1 ]
Li, Jie [2 ]
Wang, Siwang [1 ]
机构
[1] Northwest Univ, Coll Life Sci, Biomed Key Lab Shaanxi Prov, Xian 710069, Peoples R China
[2] Air Force Med Univ, Sch Pharm, Dept Chinese Mat Med & Nat Med, Xian 710032, Peoples R China
关键词
Peony pollen; Benign prostatic hyperplasia; Network pharmacology; Target prediction; Molecular docking; URINARY-TRACT SYMPTOMS; PLANT FLAVONE; CYCLOOXYGENASE-2; WOGONIN; EPIDEMIOLOGY; SUPPRESSION; CHRYSIN;
D O I
10.1016/j.heliyon.2023.e22212
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Paeonia suffruticosa is widely cultivated globally due to its medicinal and ornamental value. Peony pollen (PP) is commonly used in Chinese folk medicine to make tea to treat benign prostatic hyperplasia (BPH), but its molecular mechanism against BPH is yet to be comprehended. The objective of this research was to experimentally verify the effect of PP in the treatment of BPH and to preliminarily reveal its mechanism of action on BPH using network pharmacology methods. The results revealed that PP could decrease prostate volume and prostate index, serum testos-terone (T), dihydrotestosterone (DHT), and estradiol (E2) levels. Moreover, it could improve prostate tissue structure in BPH model animals as well. Additionally, database searches and disease target matching revealed 81 compounds in PP. Of these, 3, 7, 8, 2 '-tetrahydroxyflavone, Chrysin, Wogonin, Limocitrin, and Sexangularetin were the top five compounds associated with the therapeutic effects of BPH. Furthermore, 177 therapeutic targets for BPH were retrieved from databases of Swiss Target, DisGeNET, Drugbank, Genecards, OMIM, TTD, and Uniprot. In contrast, core targets AKT1, EGFR, IL6, TNF, and VEGFA were obtained by PPI network diagram. Molecular docking also showed that the main efficacy components and potential core targets in PP had good binding capacity. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomics (KEGG) analysis established that the effect of PP in BPH therapy was mainly through regulating the expression levels of protein kinase B on phosphatidylinositol 3-kinase and phosphatidylinositol 3-kinase-protein kinase B pathways. Additionally, Western blot experiments also exhibited a significant elevation in the activated PI3K and AKT proteins in the model (Mod) group relative to the control (Con) group, and the expression of these activated proteins was significantly reduced after PP administration. In summary, this research provides a scientific basis for employing PP to treat BPH, preliminarily reveals its mechanism of action and potential targets, and lays the foundation for further research and development.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Treating Benign Prostatic Hyperplasia with Botulinum Neurotoxin
    Brisinda, G.
    Vanella, S.
    Marniga, G.
    Crocco, A.
    Maria, G.
    CURRENT MEDICINAL CHEMISTRY, 2011, 18 (23) : 3468 - 3475
  • [2] Epidemiology of benign prostatic hyperplasia
    Robert, G.
    De La Taille, A.
    Descazeaud, A.
    PROGRES EN UROLOGIE, 2018, 28 (15): : 803 - 812
  • [3] Prostatic artery embolization in treating benign prostatic hyperplasia: a systematic review
    Teoh, Jeremy Y. C.
    Chiu, Peter K. F.
    Yee, Chi-Hang
    Wong, Hon-Ming
    Chan, Chi-Kwok
    Chan, Eddie S. Y.
    Hou, Simon S. M.
    Ng, Chi-Fai
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2017, 49 (02) : 197 - 203
  • [4] Study on mechanism of Zishen Pill treating benign prostatic hyperplasia based on serum pharmacochemistry and network pharmacology
    Wang, Yao
    Liu, Lili
    Cheng, Cheng
    Wang, Shuxuan
    Zhai, Qirui
    Song, Yunyang
    Dai, Ronghua
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2023, 234
  • [5] Benign Prostatic Hyperplasia
    Langan, Robert C.
    PRIMARY CARE, 2019, 46 (02): : 223 - +
  • [6] Evaluation of intermittent tamsulosin in treating symptomatic patients with benign prostatic hyperplasia
    Soliman, Mohamed G.
    Al-Ghadeer, Mohammed R.
    Al-Shabaan, Hasan R.
    Al-Hamrani, Amer H.
    AlGhadeer, Hussain Adil
    UROLOGY ANNALS, 2023, 15 (01) : 43 - 47
  • [7] Benign prostatic hyperplasia
    Hernandez, Sarelis Infante
    Rivas, Juan Gomez
    Sierra, Jesus Moreno
    MEDICINA CLINICA, 2024, 163 (08): : 407 - 414
  • [8] Exploring the mechanism of action of the combination of cinnamon and motherwort in the treatment of benign prostatic hyperplasia: A network pharmacology study
    Yang, Jiutian
    Ma, Dongyue
    Zhao, Ziwei
    Guo, Jun
    Ren, Kai
    Wang, Fu
    MEDICINE, 2024, 103 (17) : E37902
  • [9] The mechanism of epristeride against benign prostatic hyperplasia
    Sun, ZY
    Wu, HY
    Wang, MY
    Tu, ZH
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 371 (2-3) : 227 - 233
  • [10] The mechanism of Lingze tablets in the treatment of benign prostatic hyperplasia based on network pharmacology and molecular docking technology
    Chen Shaofeng
    Li Chunxu
    Geng Qiang
    ANDROLOGIA, 2022, 54 (10)